Summary
GlobalData, the industry analysis specialist, has released its new report, “Acute Heart Failure – Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Acute Heart Failure market. The report identifies the key trends shaping and driving the global Acute Heart Failure market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acute Heart Failure sector.
Acute Heart Failure – Pipeline Assessment and Market Forecasts to 2017
Market Research
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates the acute heart failure (AHF) therapeutics market to be valued at $2.6 billion in 2009. The market is estimated to grow up to $3.2 billion in 2017, with a CAGR of 2.5%. Growth in the AHF market will be driven by the increasing number of patients. New drugs might not impact the annual cost of therapy as most of the AHF patients continue their treatment after hospitalization. The US is the largest market for AHF and it contributes to approximately 45% of the global market.
Scope
The report provides information on the key drivers and challenges of the Acute Heart Failure market. Its scope includes:
- Annualized global Acute Heart Failure market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Vasopressin V2 receptor antagonist, Renin Inhibitor, Loop Diuretic, NPR-B Agonist ,SGC Activator, cGMP-activator, Na+/K+ ATPase Inhibitor.
- Analysis of the current and future competition in the global Acute Heart Failure market. Key market players covered are Biogen Idec, Novartis, Nile Therapeutics, Bayer AG, Cardioxyl Pharma, Pharis biotech, Debiopharm.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Acute Heart Failure therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Acute Heart Failure market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Acute Heart Failure market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Acute Heart Failure market landscape? – Identify, understand and capitalize.
